PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION
暂无分享,去创建一个
P. Cuijpers | J. Reginster | N. Waugh | M. Mckee | R. Bertollini | F. Sassi | B. Jönsson | D. McDaid | W. Ricciardi | C. Chouaid | W. Dab | J. Espín | Anita Patel | D. Tordrup | T. Sach | V. P. Rupel | C. Léonard | J. Miguel | J. M. van Dongen | M. Rutten-van Molken | V. Rupel
[1] P. Gøtzsche,et al. “Adaptive pathways” to drug authorisation: adapting to industry? , 2016, British Medical Journal.
[2] P. Cuijpers,et al. Economic evidence for the clinical management of major depressive disorder: a systematic review and quality appraisal of economic evaluations alongside randomised controlled trials , 2016, Epidemiology and Psychiatric Sciences.
[3] D. Cohen. Attacks on publicly funded trials: what happens when industry does not want to know the answer , 2015, BMJ : British Medical Journal.
[4] M. Miravitlles,et al. Economic valuation and determinants of informal care to disabled people with Chronic Obstructive Pulmonary Disease (COPD) , 2015, BMC Health Services Research.
[5] Karl Claxton,et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.
[6] G. Pietri,et al. Market Access and Reimbursement: The Increasing Role of Real-World Evidence. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[7] J. Jansson,et al. External validity of the ARISTOTLE trial in real-life atrial fibrillation patients. , 2014, Cardiovascular therapeutics.
[8] MayPeter,et al. Economic Impact of Hospital Inpatient Palliative Care Consultation: Review of Current Evidence and Directions for Future Research , 2014 .
[9] M. Stevenson,et al. Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review , 2014, Current Rheumatology Reports.
[10] A. Woodcock,et al. Obtaining real-world evidence: the Salford Lung Study , 2014, Thorax.
[11] A. Brennan,et al. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] D. Tashkin,et al. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease , 2013, Respiratory Research.
[13] A. Brennan,et al. Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community , 2013, BMC Health Services Research.
[14] Chris Salisbury,et al. Implications of comorbidity for primary care costs in the UK: a retrospective observational study. , 2013, The British journal of general practice : the journal of the Royal College of General Practitioners.
[15] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] Bernadette A. Thomas,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[17] Bernadette A. Thomas,et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[18] Hazel Squires,et al. Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[19] S. Wyke,et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.
[20] L. Radbruch,et al. Enhancing patient-reported outcome measurement in research and practice of palliative and end-of-life care , 2012, Supportive Care in Cancer.
[21] J. Kang,et al. Anti-Obesity Drugs: A Review about Their Effects and Safety , 2012, Diabetes & metabolism journal.
[22] P. Oh,et al. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada , 2011, BMC health services research.
[23] R. Holle,et al. Multimorbidity and health-related quality of life in the older population: results from the German KORA-Age study , 2011, Health and quality of life outcomes.
[24] S. Simoens. Pricing and reimbursement of orphan drugs: the need for more transparency , 2011, Orphanet journal of rare diseases.
[25] I. Higginson,et al. Implementing patient reported outcome measures (PROMs) in palliative care - users' cry for help , 2011, Health and quality of life outcomes.
[26] M. Sculpher,et al. Bridging the gap between methods research and the needs of policy makers: A review of the research priorities of the National Institute for Health and Clinical Excellence , 2011, International Journal of Technology Assessment in Health Care.
[27] K. Tham,et al. Combined life satisfaction of persons with stroke and their caregivers: associations with caregiver burden and the impact of stroke , 2011, Health and quality of life outcomes.
[28] W. Brouwer,et al. Willingness to pay for a quality-adjusted life-year: the individual perspective. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[29] Reinhard Busse,et al. Tackling Chronic Disease in Europe: Strategies, Interventions and Challenges , 2010 .
[30] R. Ferner,et al. New drugs for old: disinvestment and NICE , 2010, BMJ : British Medical Journal.
[31] Kristian Lampe,et al. Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA , 2009, International Journal of Technology Assessment in Health Care.
[32] K. Chalkidou,et al. Comparative effectiveness research priorities: Identifying critical gaps in evidence for clinical and health policy decision making , 2009, International Journal of Technology Assessment in Health Care.
[33] J. Coast,et al. Use of economic evaluation in local health care decision-making in England: a qualitative investigation. , 2009, Health policy.
[34] J. Hiller,et al. Exploring policy-makers’ perspectives on disinvestment from ineffective healthcare practices , 2008, International Journal of Technology Assessment in Health Care.
[35] Stephen W Lagakos,et al. Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.
[36] J. Hiller,et al. Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices , 2007, Australia and New Zealand health policy.
[37] D. Mannino,et al. Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.
[38] P. Littlejohns,et al. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service? , 2007, Journal of health services research & policy.
[39] K. Khunti,et al. The prevalence of co‐morbid depression in adults with Type 2 diabetes: a systematic review and meta‐analysis , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[40] R. Baltussen,et al. Priority setting of health interventions: the need for multi-criteria decision analysis , 2006, Cost effectiveness and resource allocation : C/E.
[41] James Christie,et al. Economic evaluation databases as an aid to healthcare decision makers and researchers , 2005, Expert review of pharmacoeconomics & outcomes research.
[42] P. Buser,et al. Incremental Cost-Effectiveness of Drug-Eluting Stents Compared With a Third-Generation Bare-Metal Stent in a Real-World Setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET) , 2005 .
[43] Christoph Kaiser,et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET) , 2005, The Lancet.
[44] R. Willke,et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[45] David Parkin,et al. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.
[46] S. Currie,et al. Chronic back pain and major depression in the general Canadian population , 2004, Pain.
[47] Richard Birtwhistle,et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. , 2003, BMC medical research methodology.
[48] D. Banta. The development of health technology assessment. , 2003, Health policy.
[49] Laura E. Gibbons,et al. Assessing Quality of Life in Older Adults With Cognitive Impairment , 2002, Psychosomatic medicine.
[50] S. Yusuf,et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.
[51] L. Abenhaim,et al. Smoking. A risk factor for development of low back pain in adolescents. , 1999, Spine.
[52] S. Hecht,et al. Tobacco smoke carcinogens and lung cancer. , 1999, Journal of the National Cancer Institute.
[53] C Bain,et al. Threats to Applicability of Randomised Trials: Exclusions and Selective Participation , 1999, Journal of health services research & policy.
[54] J. Coebergh,et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. , 1998, Lung cancer.
[55] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[56] A. Forster,et al. Incidence and consequences offalls due to stroke: a systematic inquiry , 1995, BMJ.
[57] W C Willett,et al. A prospective study of exercise and incidence of diabetes among US male physicians. , 1992, JAMA.
[58] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.
[59] R B D'Agostino,et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. , 1988, JAMA.
[60] Karl Claxton,et al. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? , 2015, Health economics.
[61] Pepijn Vemer,et al. RESEARCH AGENDA FOR HEALTH ECONOMIC EVALUATION , 2014 .
[62] R. Morrison,et al. Economic impact of hospital inpatient palliative care consultation: review of current evidence and directions for future research. , 2014, Journal of palliative medicine.
[63] M. Suhrcke,et al. The economics of the social determinants of health and health inequalities: a resource book , 2013 .
[64] A. Harris,et al. Cost-Effectiveness Analysis and the Consistency of Decision Making , 2012, PharmacoEconomics.
[65] M. Buxton,et al. Economic Evaluation and Decision Making in the UK , 2012, PharmacoEconomics.
[66] Financial Affairs. Joint report on health systems , 2010 .
[67] Elias Mossialos,et al. Financing health care in the European Union: challenges and policy responses , 2009 .
[68] M. Neyt,et al. Threshold values for cost-effectiveness in health care KCE reports , 2009 .